Stockreport

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics, Inc.  (NMRA) 
PDF Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and ex [Read more]